Clinical Trials on ADH Inappropriate in South Africa

Total 52 results

Seattle Children's Hospital
American Academy of Pediatrics

Completed

SOFI: A Quality Improvement Project to Standardize Use of Intravenous Fluids in Hospitalized Pediatric Patients (SOFI)

Fluid and Electrolyte Imbalance | Intravenous Fluids | ADH Inappropriate

United States
Faculty of Medicine

Completed

Uterotonic Efficacy of Oxytocin 2.5 Versus 10 Units During Caesarean Section at Mulago Hospital

Uterine Hemorrhage | Adverse Effect of Oxytocic Drugs | Inappropriate Dose of Drug Administered

Uganda
Eagle Pharmaceuticals, Inc.

Completed

A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients

Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is Appropriate

United States
Supernus Pharmaceuticals, Inc.

Completed

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD

ADHD

United States
Supernus Pharmaceuticals, Inc.

Completed

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD

ADHD

United States
University of Sheffield

Active, not recruiting

Does Cultivating Self-compassion Improve Resilience to Criticism and Improve Mental Health in Adults With ADHD?

Depression | Wellbeing | Stress | Anxiety | ADHD | Self-Criticism | Self-compassion

United Kingdom
Medical University of South Carolina
Shire

Completed

Evaluating the Methylphenidate Patch to Treat Former Stimulant Users With ADHD

Adult Attention Deficit Hyperactivity Disorder (ADHD)

United States
Noven Therapeutics

Completed

Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

ADHD

United States
Rhodes Pharmaceuticals, L.P.
Purdue Pharma LP

Completed

PRC-063 in Adolescent ADHD

ADHD

United States, Canada
Shire

Completed

Drug Use Study With Intuniv® in Australia

Attention Deficit Hyperactivity Disorder (ADHD)

Australia
Cingulate Therapeutics

Recruiting

Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301

ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit Hyperactivity

United States
Arbor Pharmaceuticals, Inc.

Completed

AR08 for Treatment of ADHD in Children

ADHD

United States
Arbor Pharmaceuticals, Inc.

Completed

Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Noven Therapeutics

Completed

Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

ADHD

United States
Cephalon

Completed

Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD

ADHD

United States
UK Kidney Association

Recruiting

National Registry of Rare Kidney Diseases (RaDaR)

Vasculitis | AL Amyloidosis | Tuberous Sclerosis | Fabry Disease | Cystinuria | Focal Segmental Glomerulosclerosis | IgA Nephropathy | Bartter Syndrome | Pure Red Cell Aplasia | Membranous Nephropathy | Atypical Hemolytic Uremic Syndrome | Autosomal Dominant Polycystic Kidney Disease | Cystinosis | Nephronophthisis | BK Nephropathy and other conditions

United Kingdom
Axsome Therapeutics, Inc.

Recruiting

A Study to Access the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)

ADHD

United States
Shire

Completed

Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study

ADHD

United States
Atridia Pty Ltd.

Not yet recruiting

A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Alzheimer's Disease (AD)

Australia
Shire

Completed

Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17

ADHD

Germany, Hungary, Italy, Poland, Sweden, United States, United Kingdom, Belgium, France
Neurocentria, Inc.

Completed

Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)

ADHD

United States
Supernus Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)

Impulsive Aggression Comorbid With ADHD

United States
Cingulate Therapeutics
Premier Research Group plc

Active, not recruiting

Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301

ADHD | Attention Deficit Hyperactivity Disorder | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit Hyperactivity

United States
Shire

Completed

Efficacy and Safety of SPD503 in Combination With Psychostimulants

ADHD

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

Attention-Deficit/Hyperactivity Disorder (ADHD)

United States
Eli Lilly and Company

Completed

Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse

ADHD | Comorbid Alcohol Abuse

United States, Canada
Shire

Completed

Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Neurocentria, Inc.

Recruiting

Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD (ADHD)

Attention-Deficit/Hyperactivity Disorder (ADHD)

United States
Sunovion

Completed

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

Attention-Deficit Hyperactivity Disorder (ADHD)

United States
Calcilytix Therapeutics, Inc., a BridgeBio company

Recruiting

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 (CALIBRATE)

Autosomal Dominant Hypocalcemia (ADH)

United States, Australia, Denmark, Italy, France, Japan, Canada, Czechia, Netherlands
Supernus Pharmaceuticals, Inc.

Completed

Open-Label, Extension Study to 810P202

Impulsive Aggression Comorbid With ADHD in Children

United States
National Cancer Institute (NCI)

Suspended

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

Diffuse Glioma | Secondary Glioblastoma | Glioblastoma, IDH-Wildtype | Astrocytoma, IDH-Mutant, Grade 4

United States, Puerto Rico
Shire

Completed

Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Cephalon

Completed

Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD

ADHD | Attention Deficit Hyperactivity Disorder

United States
Alcobra Ltd.

Terminated

The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD

Attention Deficit Hyperactivity Disorder (ADHD)

United States, Israel
University of Cincinnati
National Institute on Drug Abuse (NIDA); University of Colorado, Denver

Completed

Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)

ADHD | Substance Abuse

United States
Abbott

Completed

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

ADHD | Attention-Deficit/Hyperactivity Disorder

United States
Supernus Pharmaceuticals, Inc.

Completed

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Alcobra Ltd.

Completed

A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )

ADHD | Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type

United States, Israel
Shire

Completed

Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Terminated

Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Completed

Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Completed

Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder (ADHD)

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Recurrent Glioblastoma | Diffuse Astrocytoma, IDH-Wildtype

United States
Shire

Completed

Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Supernus Pharmaceuticals, Inc.

Completed

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Completed

Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Institut de Recherches Internationales Servier
Celgene Corporation

Active, not recruiting

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Untreated AML | Newly Diagnosed Acute Myeloid Leukemia (AML) | AML Arising From Myelodysplastic Syndrome (MDS) | AML Arising From Antecedent Hematologic Disorder (AHD) | AML Arising After Exposure to Genotoxic Injury

United States, Germany, Netherlands
AbbVie

Recruiting

Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease

Alzheimer's Disease (AD)

United States, Japan, New Zealand, Australia, Spain, Germany, United Kingdom
University of Southern California
National Institute on Aging (NIA); Northern California Institute of Research... and other collaborators

Recruiting

Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) (ADNI3)

Mild Cognitive Impairment (MCI) | Alzheimer's Disease (AD)

United States, Canada

Clinical Trials on ADH Inappropriate in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations